Vnitr Lek 2024, 70(6):358-365 | DOI: 10.36290/vnl.2024.072

Rheumatoid arthritis as an internal disease

Martina Skácelová, Pavel Horák
III. interní klinika - nefrologická, revmatologická a endokrinologická, FN a LF UP Olomouc

Rheumatoid arthritis (RA) is an autoimunne disease that, in addition to persistent synovial inflammation with bone destruction and cartilage loss, can manifest a variety of extra-articular symptoms and associated comorbidities that can significantly affect the quality of life of patients or limit the treatment options for RA. Extraarticular manifestations include skin, eye, mucous membrane, lung or pleural involvement, and less commonly heart a kidney involvement. The higher mortality and morbidity in RA patients is due to the high prevalence of comorbidities. These include cardiovascular diseases, infections, solid tumors and lymfomas, lung and gastrointestinal diseases, neuropsychiatric diseases, especially depression and osteoporosis.

Keywords: rheumatoid arthritis, extraarticular manifestations, comorbidities.

Accepted: September 19, 2024; Published: October 3, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Skácelová M, Horák P. Rheumatoid arthritis as an internal disease. Vnitr Lek. 2024;70(6):358-365. doi: 10.36290/vnl.2024.072.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Turesson C, O'Fallon WM, Crowson CS, et al. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis. 2003;62:722. Go to original source... Go to PubMed...
    2. Myasoedova E, Crowson CS, Turesson C, et al. Incidence of extraarticular rheumatoid arthritis in Olmsted County, Minnesota, in 1995-2007 versus 1985-1994: a population-based study. J Rheumatol. 2011;8:983. Go to original source... Go to PubMed...
    3. Guellec D, Cozien S, Ruyssen-Witrand A, et al. Prevalence and clinical significance of extra-articular manifestations at diagnosis in the ESPOIR cohort with recent-onset arthritis. Semin Arthritis Rheum. 2020;50:409. Go to original source... Go to PubMed...
    4. Chandrashekara S, Shobha V, Dharmanand BG, et al. Reduced incidence of extra-articular manifestations of RA through effective disease control: Karnataka Rheumatoid Arthritis Comorbidity (KRAC) study. Int J Rheum Dis 2017; 20:1694. Go to original source... Go to PubMed...
    5. Wolfe F, Mitchell DM, Sibley JT, et al. Th e mortality of rheumatoid arthritis. Arthritis Rheum. 1994;4:481-494. Go to original source... Go to PubMed...
    6. Duffield SJ, Miller N, Zhao S, Goodson NJ. Concomitant fibromyalgia complicating chronic inflammatory arthritis: a systematic review and meta-analysis. Rheumatology (Oxford) 2018;57:1453. Go to original source...
    7. Turk MA, Hayworth JL, Nevskaya T, Pope JE. Ocular Manifestations in Rheumatoid Arthritis, Connective Tissue Disease, and Vasculitis: A Systematic Review and Metaanalysis. J Rheumatol. 2021;48:25. Go to original source... Go to PubMed...
    8. Silva B, Cardozo J, Marback P, Machado F, Galvão V, Santiago M. Peripheral ulcerative keratitis: a serious complication of rheumatoid arthritis. Rheum Int. 2010;30(9):1267-8. Go to original source... Go to PubMed...
    9. Turesson C, Jacobsson LT. Epidemiology of extra-articular manifestations in rheumatoid arthritis. Scand J Rheumatol. 2004;33:65. Go to original source... Go to PubMed...
    10. Kimbrough BA, Crowson CS, Davis JM 3rd, et al. Decline in Incidence of Extra-Articular Manifestations of Rheumatoid Arthritis: A Population-Based Cohort Study. Arthritis Care Res (Hoboken) 2024;76:454. Go to original source... Go to PubMed...
    11. Patatanian E, Thompson DF. A review of methotrexate-induced accelerated nodulosis. Pharmacotherapy. 2002;22:1157. Go to original source... Go to PubMed...
    12. Maldonado I, Eid H, Rodriguez GR, et al. Rheumatoid nodulosis: is it a different subset of rheumatoid arthritis? J Clin Rheumatol. 2003;9:296. Go to original source... Go to PubMed...
    13. Balbir-Gurman A, Yigla M, Nahir AM, Braun-Moscovici Y. Rheumatoid pleural effusion. Semin Arthritis Rheum. 2006;35:368. Go to original source... Go to PubMed...
    14. Lawry GV, Finerman ML, Hanafee WN, et al. Laryngeal involvement in rheumatoid arthritis. A clinical, laryngoscopic, and computerized tomographic study. Arthritis Rheum. 1984;27:873. Go to original source... Go to PubMed...
    15. Greco A, Fusconi M, Macri GF, et al. Cricoarytenoid joint involvement in rheumatoid arthritis: radiologic evaluation. Am J Otolaryngol. 2012;33:753. Go to original source... Go to PubMed...
    16. Devouassoux G, Cottin V, Lioté H, et al. Characterisation of severe obliterative bronchiolitis in rheumatoid arthritis. Eur Respir J. 2009;33:1053. Go to original source... Go to PubMed...
    17. Remy-Jardin M, Remy J, Cortet B, et al. Lung changes in rheumatoid arthritis: CT findings. Radiology. 1994;193:375. Go to original source... Go to PubMed...
    18. Bongartz T, Nannini C, Medina-Velasquez YF, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2010;62:1583-1591. Go to original source... Go to PubMed...
    19. Hyldgaard C, Hilberg O, Pedersen AB, et al. A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality. Ann Rheum Dis. 2017;76:1700-1706. Go to original source... Go to PubMed...
    20. Hyldgaard C, Ellingsen T, Hilberg O, et al. Rheumatoid arthritis-associated interstitial lung disease: clinical characteristics and predictors of mortality. Respiration. 2019;98:455-460. Go to original source... Go to PubMed...
    21. Kadura S, Raghu G. Rheumatoid arthritis-interstitial lung disease: manifestations and current concepts in pathogenesis and management. Eur Respir Rev. 2021 Jun 23;30(160):210011. Go to original source... Go to PubMed...
    22. Mertz P, Wollenschlaeger C, Chasset F, et al. Rheumatoid vasculitis in 2023: Changes and challenges since the biologics era. Autoimmun Rev. 2023;22:103391. Go to original source... Go to PubMed...
    23. Karie S, Gandjbakhch F, Janus N, et al. Kidney disease in RA patients: prevalence and implication on RA-related drugs management: the MATRIX study. Rheumatology (Oxford) 2008;47:350. Go to original source...
    24. Hickson LJ, Crowson CS, Gabriel SE, et al. Development of reduced kidney function in rheumatoid arthritis. Am J Kidney Dis. 2014;63:206. Go to original source... Go to PubMed...
    25. Sim MK, Kim DY, Yoon J, Park DH, Kim YG. Assessment of peripheral neuropathy in patients with rheumatoid arthritis who complain of neurologic symptoms. Ann Rehabil Med. 2014 Apr;38(2):249-55. Go to original source... Go to PubMed...
    26. Owlia MB, Newman K, Akhtari M. Felty's Syndrome, Insights and Updates. Open Rheumatol J. 2014 Dec 31;8:129-36. Go to original source... Go to PubMed...
    27. Gridley G, Klippel JH, Hoover RN, Fraumeni JF Jr. Incidence of cancer among men with the Felty syndrome. Ann Intern Med. 1994;120:35. Go to original source... Go to PubMed...
    28. Wolfe F, Mitchell DM, Sibley JT, et al. The mortality of rheumatoid arthritis. Arthritis Rheum. 1994;4:481-494. Go to original source... Go to PubMed...
    29. Dougados M, Soubrier M, Antunez A, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis. 2014;1:62-68. Go to original source... Go to PubMed...
    30. Oreská S, Tomčík M. KV riziko u revmatických onemocnění. Cas Lek Cesk. 2016;155(6):324-332.
    31. Luque Ramos A, Redeker I, Hoffmann F, Callhoff J, Zink A, Albrecht K. Comorbidities in Patients with Rheumatoid Arthritis and Their Association with Patient-reported Outcomes: Results of Claims Data Linked to Questionnaire Survey. J Rheumatol. 2019 Jun;46(6):564-571. Go to original source... Go to PubMed...
    32. Rollefstad S, Ikdahl E, Wibetoe G, et al. An international audit of the management of dyslipidaemia and hypertension in patients with rheumatoid arthritis-results from 19 countries. Eur Heart J Cardiovasc Pharmacother. 2022:6:539-548. Go to original source... Go to PubMed...
    33. Semb AG, Rollefstad S, Ikdahl E, et al. Diabetes mellitus and cardiovascular risk management in patients with rheumatoid arthritis: an international audit. RMD Open. 2021;2:e001724. doi: 10.1136/rmdopen-2021-001724. Go to original source... Go to PubMed...
    34. Agca R, Hopman LHGA, Laan KJC, et al. Cardiovascular Event Risk in Rheumatoid Arthritis Compared with Type 2 Diabetes: A 15-year Longitudinal Study. J Rheumatol. 2020;3:316-324. Go to original source... Go to PubMed...
    35. Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Annals of the Rheumatic Diseases 2017;76:17-28. Go to original source... Go to PubMed...
    36. Drosos GC, Vedder D, Houben E, et al. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis. 2022 Jun;81(6):768-779. Go to original source... Go to PubMed...
    37. Omair MA, Alkhelb SA, Ezzat SE, et al. Venous Thromboembolism in Rheumatoid Arthritis: The Added Effect of Disease Activity to Traditional Risk Factors. Open Access Rheumatol. 2022 Oct 17;14:231-242. Go to original source... Go to PubMed...
    38. Thomas K, Vassilopoulos D. Infections in Patients with Rheumatoid Arthritis in the Era of Targeted Synthetic Therapies. Mediterr J Rheumatol. 2020 Jun 11;31(Suppl 1):129-136. Go to original source... Go to PubMed...
    39. Mehta B, Pedro S, Ozen G, et al. Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases: a US national cohort study. RMD Open. 2019;1:e000935. doi: 10.1136/ rmdopen-2019-000935. Go to original source... Go to PubMed...
    40. Accortt NA, Lesperance T, Liu M, et al. Impact of Sustained Remission on the Risk of Serious Infection in Patients With Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2018 May;70(5):679-684. doi: 10.1002/acr.23426. Epub 2018 Mar 11. Go to original source... Go to PubMed...
    41. Lacaille D, Guh DP, Abrahamowicz M, et al. Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. Arthritis Rheum. 2008;59:1074. Go to original source... Go to PubMed...
    42. Bechman K, Subesinghe S, Norton S, et al. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford) 2019;58:1755. Go to original source... Go to PubMed...
    43. Beydon M, Pinto S, De Rycke Y, et al. Risk of cancer for patients with rheumatoid arthritis versus general population: a national claims database cohort study. Lancet Reg Health Eur. 2023 Oct 30;35:100768. Go to original source... Go to PubMed...
    44. Lange E, Blizzard L, Venn A,et al. Disease-modifying anti-rheumatic drugs and non-melanoma skin cancer in inflammatory arthritis patients: a retrospective cohort study. Rheumatology (Oxford). 2016 Sep;55(9):1594-600. Go to original source... Go to PubMed...
    45. Wang JL, Yin WJ, Zhou LY, et al. Risk of non-melanoma skin cancer for rheumatoid arthritis patients receiving TNF antagonist: a systematic review and meta-analysis. Clin Rheumatol. 2020 Mar;39(3):769-778.Další literatura u autorky a na www.casopisvnitrnilekarstvi.cz Go to original source... Go to PubMed...
    46. Kim SY, Min C, Oh DJ, Choi HG. Increased risk of asthma in patients with rheumatoid arthritis: A longitudinal follow-up study using a national sample cohort. Sci Rep. 2019 May 6;9(1):6957. Go to original source... Go to PubMed...
    47. Ma Y, Tong H, Zhang X, et al. Chronic obstructive pulmonary disease in rheumatoid arthritis: a systematic review and meta-analysis. Respir Res. 20,144(2019). Go to original source... Go to PubMed...
    48. Moshayedi S, Tasorian B, Almasi-Hashiani A. The prevalence of osteoporosis in rheumatoid arthritis patient: a systematic review and meta-analysis. Sci Rep. 2022 Sep 23;12(1):15844. Go to original source... Go to PubMed...
    49. Wysham KD, Baker JF, Shoback DM. Osteoporosis and fractures in rheumatoid arthritis. Curr Opin Rheumatol. 2021;3:270-276. Go to original source... Go to PubMed...
    50. Matcham F, Rayner L, Steer S, et al. The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology (Oxford). 2013;12:2136-2148. Go to original source... Go to PubMed...
    51. Margaretten M, Julian L, Katz P, Yelin E. Depression in patients with rheumatoid arthritis: description, causes and mechanisms. Int J Clin Rheumtol. 2011;6(6):617-623. Go to original source...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.